Jubilant Pharmova share news, announcements and annual reports
NSE: JUBLPHARMABSE: 530019Pharmaceuticals & BiotechnologySmall Cap
Jubilant Pharmova Limited · Formerly Jubilant Life Sciences · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 1981 on BSE, Jun 2003 on NSE
Last close ₹923.80down ₹22.20 (2.35%)BSE ₹924.70
Share price at the NSE close on 30 Oct 2026. Previous close ₹946.00.
30 Oct: open ₹946.00, high ₹951.80, low ₹920.00
52-week range of traded prices to 30 Oct 2026
₹786.05Low, 9 Mar 2026₹1,183.00High, 4 Nov 2025
- Next results date: the board meets on 13 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹14,714 Cr422nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 41.79
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 35.78
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.07
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.54%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 5.3%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 6.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.45
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 56,22937.1% delivered
Jubilant Pharmova board meetings
113 filed, newest first. Page 3 of 3.
Oct 2009
14 Oct · Board meeting
Meeting on 22 Oct 2009: “Unaudited Financial Results for the Qtr ended Sept 30, 2009/Unaudited Financial Results/Others”
Jul 2009
6 Jul · Board meeting
To inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2009.
Apr 2009
20 Apr · Board meeting
To inter-alia consider: (1) Audited Financial Results of the Company for the year ended March 31, 2009. (2) Recommendation of Dividend for the year ended March 31, 2009.
Jan 2009
19 Jan · Board meeting
Meeting on 27 Jan 2009: “Unaudited Financial Results for the qtr ended Dec 31, 2008”
Oct 2008
6 Oct · Board meeting
To inter-alia consider and take on record the Unaudited Financial Results of the Company for the quarter ended September 30, 2008.
Jul 2008
7 Jul · Board meeting
Meeting on 15 Jul 2008: “Unaudited Financial Results for the Qtr ended June 30, 2008”
Apr 2008
11 Apr · Board meeting
To inter-alia consider: (1) Audited Financial Results of the Company for the year ended March 31, 2008. (2) Recommendation of Dividend for the year ended March 31, 2008.
Jan 2008
9 Jan · Board meeting
Meeting of the Board of Directors, which was scheduled for January 15, 2008 inter-alia, to consider and take on record, the Unaudited Financial Results of the Company for the quarter ended December 31, 2007, has been postponed and will now be held on January 30, 2008.4 Jan · Board meeting
Meeting on 15 Jan 2008: “Unaudited Financial Results for the qtr ended Dec 31, 2007”
Oct 2007
4 Oct · Board meeting
To inter alia consider and take on record the Unaudited Financial Results of the Company for the quarter ended September 30, 2007.
Jul 2007
9 Jul · Board meeting
Meeting on 17 Jul 2007: “Unaudited financial results for quarter ended June 30, 2007”
Apr 2007
18 Apr · Board meeting
To inter-alia consider: (1) Audited Financial Results of the Company for the year ended March 31, 2007. (2) Recommendation of Dividend for the year ended March 31, 2007.
Jan 2007
5 Jan · Board meeting
To inter-alia consider and take on record the Unaudited Financial Results of the Company for the quarter ended December 31, 2006.